Cita APA

Rha, S., Oh, D., Yañez, P., Bai, Y., Ryu, M., Lee, J., . . . Castro-Oliden, V. (2023). Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): A multicentre, randomised, double-blind, phase 3 trial.

Citación estilo Chicago

Rha, SY, et al. Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for HER2-negative Advanced Gastric Cancer (KEYNOTE-859): A Multicentre, Randomised, Double-blind, Phase 3 Trial. 2023.

Cita MLA

Rha, SY, et al. Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for HER2-negative Advanced Gastric Cancer (KEYNOTE-859): A Multicentre, Randomised, Double-blind, Phase 3 Trial. 2023.